|
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
Cook D, Douketis J, Meade M, et al. |
|
Crit Care. 2008 Mar 3;12(2):R32 |
|
|
|
Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial
Mahaffey KW, Yang Q, Pieper KS, et al. |
|
J Gen Intern Med. 2008 Jan 15 [Epub ahead of print] |
|
|
|
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial
Morrow DA, Antman EM, Murphy SA, et al. |
|
Am Heart J. 2007 Dec;154(6):1078-84, 1084.e1 |
|
|
|
Idraparinux versus standard therapy for venous thromboembolic disease
van Gogh Investigators, Buller HR, et al. |
|
N Engl J Med. 2007 Sep 13;357(11):1094-104 |
|
|
|
Extended prophylaxis of venous thromboembolism with idraparinux
van Gogh Investigators, Buller HR, Cohen AT, et al. |
|
N Engl J Med. 2007 Sep 13;357(11):1105-12 |
|
|
|
Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial
Steinberg BA, Moghbeli N, Buros J, et al. |
|
Am Heart J. 2007 Jul;154(1):54-61 |
|
|
|
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, Antman EM. |
|
Eur Heart J. 2007 May;28(9):1066-71 |
|
|
|
The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators. |
|
Lancet. 2007 Apr 21;369(9570):1347-55 |
|
|
|
Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis.
Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. |
|
Thromb Res. 2007 Apr 19; |
|
|
|
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Simonneau G, Laporte S, Mismetti P, Derlon A, Samii K, Samama CM, Bergman JF; FX140 Study Investigators. |
|
J Thromb Haemost. 2006 Aug;4(8):1693-700. Epub 2006 Jun 21. |
|
|
|
Artificial reproductive technology and the risk of venous thromboembolic disease.
Nelson SM, Greer IA. |
|
J Thromb Haemost. 2006 Aug;4(8):1661-3. |
|
|
|
A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot.
Chan WS, Ginsberg JS. |
|
J Thromb Haemost. 2006 Aug;4(8):1673-7. |
|
|
|
Enoxaparin vs. nadroparin for venous thromboembolism prevention: too close to tell?
|
|
J Thromb Haemost. 2006 Aug;4(8):1691-2. |
|
|
|
Intermittent mechanical compression for prevention of travellers' thrombosis.
Coppens M, van Doormaal FF, Schreijer AJ, Rosendaal FR, Buller HR. |
|
J Thromb Haemost. 2006 Aug;4(8):1836-8. |
|
|
|
Thromboprophylaxis with graduated compression stockings for elderly inpatients: more evidence is needed.
Labarere J, Bosson JL, Sevestre MA, Boge G, Terriat B; Association pour la Promotion de L'Angiologie Hospitaliere. |
|
J Thromb Haemost. 2006 Aug;4(8):1838-40. |
|
|
|
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema. |
|
J Thromb Haemost. 2006 Aug;4(8):1842-5. |
|
|
|
Noninvasive risk stratification after myocardial infarction: new evidence, new questions.
Gibbons RJ, Miller TD. |
|
J Am Coll Cardiol. 2006 Dec 19;48(12):2468-70. Epub 2006 Nov 28. |
|
|
|
Effect of door-to-balloon time on patient mortality.
Brodie BR, Grines CL, Stone GW. |
|
J Am Coll Cardiol. 2006 Dec 19;48(12):2600; author reply 2601. Epub 2006 Nov 22. |
|
|
|
Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians
Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'gara P, Whitlow P. |
|
Circulation. 2007 Jan 15; [Epub ahead of print] |
|
|
|
Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and >80 years) (from the New York State Angioplasty Registry).
Feldman DN, Gade CL, Slotwiner AJ, et al. |
|
Am J Cardiol. 2006 Nov 15;98(10):1334-9. Epub 2006 Sep 28. |
|
|
|
Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital.
Le May MR, Davies RF, Dionne R, et al. |
|
Am J Cardiol. 2006 Nov 15;98(10):1329-33. Epub 2006 Sep 28. |
|
|
|
Effect of Clopidogrel Plus Aspirin on ST Segments in Patients With ST-Elevation Acute Myocardial Infarction.
Jabaren M, Desai DM, Arabi A, Kareti G, et al. |
|
Am J Cardiol. 2006 Dec 1;98(11):1435-8. Epub 2006 Oct 4. |
|
|
|
Bivalirudin for patients with acute coronary syndromes
Stone GW, McLaurin BT, Cox DA, et al. |
|
N Engl J Med. 2006 |
|
|
|
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
Eriksson BI, Borris LC, Dahl OE, et al. |
|
Circulation. 2006 |
|
|
|
High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction
Beygui F, Collet JP, Benoliel JJ, et al. |
|
Circulation. 2006 |
|
|
|
Coronary Intervention for Persistent Occlusion after Myocardial Infarction
Hochman JS, Lamas GA, Buller CE, et al. |
|
N Engl J Med. 2006 |
|
|
|
Prophylactic low-molecular-weight heparin: prescription practice in an intensive care unit
Tilleul P, Tredan G, Austruy G, et al. |
|
J Crit Care. 2006 Jun;21(2):173-8 |
|
|
|
Strategies for Reducing the Door-to-Balloon Time in Acute Myocardial Infarction
Bradley EH, Herrin J, Wang Y, et al. |
|
N Engl J Med. 2006 |
|
|
|
Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population
Hoppe B, Tolou F, Dorner T, et al. |
|
Thromb Haemost. 2006 Oct;96(4):465-70 |
|
|
|
Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy
Cannon CP, McLean DS. |
|
Am J Cardiol. 2006 Nov 20;98(10S1):S33-S38 |
|
|
|
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
Mehta RH, Roe MT, Chen AY, et al. |
|
Arch Intern Med. 2006 Oct 9;166(18):2027-34 |
|
|
|
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting
Cuisset T, Frere C, Quilici J, et al. |
|
J Am Coll Cardiol. 2006 Oct 3;48(7):1339-45 |
|
|
|
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
Cohen M, Mahaffey KW, Pieper K, et al. |
|
J Am Coll Cardiol. 2006 Oct 3;48(7):1346-54 |
|
|
|
Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA Trial
Galiuto L, Garramone B, Burzotta F, et al. |
|
J Am Coll Cardiol. 2006 Oct 3;48(7):1355-60 |
|
|
|
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
Mehta RH, Roe MT, Chen AY, et al. |
|
Arch Intern Med. 2006 Oct 9;166(18):2027-34 |
|
|
|
Short- and long-term prognosis after acute myocardial infarction in men versus women
Koek HL, de Bruin A, Gast F, et al. |
|
Am J Cardiol. 2006 Oct 15;98(8):993-9 |
|
|
|
Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction
Stenestrand U, Lindback J, Wallentin L, et al. |
|
JAMA. 2006 Oct 11;296(14):1749-56 |
|
|
|
Predictors of In-Hospital Mortality Difference Between Male and Female Patients With Acute Myocardial Infarction
Jiang SL, Ji XP, Zhao YX, wt al. |
|
Am J Cardiol. 2006 Oct 15;98(8):1000-1003 |
|
|
|
How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
Levine RL, McCollum D, Hursting MJ. |
|
Chest. 2006 Sep;130(3):681-7 |
|
|
|
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
Cohen M, Mahaffey KW, Pieper K, et al. |
|
J Am Coll Cardiol. 2006 Oct 3;48(7):1346-54 |
|
|
|
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS
Fuchs I, Frossard M, Spiel A, et al. |
|
J Thromb Haemost. 2006 Sep 26 |
|
|
|
Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia
Holtan SG, Knox SK, Tefferi A. |
|
J Thromb Haemost. 2006 Jul;4(7):1632-4 |
|
|
|
Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism
Quiroz R, Gerhard-Herman M, Kosowsky JM, et al. |
|
Am J Cardiol. 2006 Aug 15;98(4):535-7 |
|
|
|
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
Hussein MA. |
|
Thromb Haemost. 2006 Jun;95(6):924-30 |
|
|
|
Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: Frequency distribution in a healthy German population
Hoppe B, Tolou F, Dorner T, et al. |
|
Thromb Haemost. 2006 Oct;96(4):465-70 |
|
|
|
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative
Diercks DB, Roe MT, Mulgund J, et al. |
|
Am Heart J. 2006 Jul;152(1):140-8 |
|
|
|
Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE)
Cohen MG, Roe MT, Mulgund J, et al. |
|
Am Heart J. 2006 Jul;152(1):110-7 |
|
|
|
Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy
Alguel G, Vormittag R, Simanek R, et al. |
|
Thromb Haemost. 2006 Sep;96(3):285-9 |
|
|
|
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial
Rajagopal V, Lincoff AM, Cohen DJ, et al. |
|
Am Heart J. 2006 Jul;152(1):149-54 |
|
|
|
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
Exaire JE, Butman SM, Ebrahimi R, et al. |
|
Am Heart J. 2006 Jul;152(1):157-63 |
|
|
|
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial)
Cox DA, Stone GW, Grines CL, et al. |
|
Am J Cardiol. 2006 Aug 1;98(3):331-7. Epub 2006 Jun 9 |
|
|
|
How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
Levine RL, McCollum D, Hursting MJ. |
|
Chest. 2006 Sep;130(3):681-7 |
|
|
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Montalescot G, White HD, Gallo R, et al. |
|
N Engl J Med. 2006 Sep 7;355(10):1006-17 |
|
|
|
The metabolic syndrome and the risk of venous thrombosis: a case control study
Ageno W, Prandoni P, Romualdi E, et al. |
|
J Thromb Haemost. 2006 |
|
|
|
Early Experience with the Retrievable OptEase Vena Cava Filter in High-risk Trauma Patients
Meier C, Keller IS, Pfiffner R, et al. |
|
Eur J Vasc Endovasc Surg. 2006 |
|
|
|
Prophylactic implantation of inferior vena cava filter during interventional radiological treatment for deep venous thrombosis of the lower extremity
Yamagami T, Kato T, Hirota T, et al. |
|
Br J Radiol. 2006 Jul;79(943):584-91 |
|
|
|
Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon
Bouaziz-Borgi L, Almawi WY, Mtiraoui N, et al. |
|
Am J Hematol. 2006 Jul 5;81(8):641-643 |
|
|
|
Have palliative care teams' attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across british specialist palliative care units in the years 2000 and 2005
Noble SI, Finlay IG. |
|
J Pain Symptom Manage. 2006 Jul;32(1):38-43 |
|
|
|
Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis
Limpus A, Chaboyer W, McDonald E, et al. |
|
Am J Crit Care. 2006 Jul;15(4):402-12 |
|
|
|
A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation. The Rotterdam Study 1990-1999
Heeringa J, Conway DS, Van der Kuip DA, et al. |
|
J Thromb Haemost. 2006 |
|
|
|
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) versus enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer
Simonneau G, Laporte S, Mismetti P, et al. |
|
J Thromb Haemost. 2006 |
|
|
|
The Importance of Thrombophilia in the Treatment of Paget-Schroetter Syndrome
Cassada DC, Lipscomb AL, Stevens SL, et al. |
|
Ann Vasc Surg. 2006 |
|
|
|
Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy
Wan C, Warner M, De Varennes B, et al. |
|
Ann Thorac Surg. 2006 Jul;82(1):21-6 |
|
|
|
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism
Spencer FA, Emery C, Lessard D, et al. |
|
J Gen Intern Med. 2006 Jul;21(7):722-7 |
|
|
|
Medical management of patients with brain tumors
Wen PY, Schiff D, Kesari S, et al. |
|
J Neurooncol. 2006 |
|
|
|
Role of current and emerging antithrombotics in thrombosis and cancer
Mousa SA. |
|
Drugs Today (Barc). 2006 May;42(5):331-50 |
|
|
|
Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM study
Colonna P, Sorino M, de Luca L, et al. |
|
J Cardiovasc Med (Hagerstown). 2006 Jul;7(7):505-513 |
|
|
|
Pulmonary Embolism Associated With a Vacuum-Induced Arm Compartment Syndrome: A Setting for Increased Vigilance
Whitson BA, Barnett SJ, Huddleston SJ, et al. |
|
J Burn Care Res. 2006 July/August;27(4):552-554 |
|
|
|
Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience
Walker NE, Fasano MB, Horwitz PA. |
|
J Invasive Cardiol. 2006 Jul;18(7):341-4 |
|
|
|
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
Abramson N, Costantino JP, Garber JE, et al. |
|
J Natl Cancer Inst. 2006 Jul 5;98(13):904-10 |
|
|
|
Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia (July/August)
Efird LE, Kockler DR. |
|
Ann Pharmacother. 2006 Jun 20 |
|
|
|
Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
Rommers MK, Van Der Lely N, Egberts TC, et al. |
|
Crit Care. 2006 Jun 21;10(3):R93 |
|
|
|
Deep Vein Thrombosis following Ischemic Stroke among Asians
De Silva DA, Pey HB, Wong MC, et al. |
|
Cerebrovasc Dis. 2006 Jun 20;22(4):245-250 |
|
|
|
Acute thrombotic disorders
Kuntz JG, Cheesman JD, Powers RD. |
|
Am J Emerg Med. 2006 Jul;24(4):460-7 |
|
|
|
Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound
Gaitini D. |
|
J Clin Ultrasound. 2006 Jun 20;34(6):289-297 |
|
|
|
The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology
Winter PC. |
|
Hematol Oncol. 2006 |
|
|
|
Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia
Lewis BE, Wallis DE, Hursting MJ, et al. |
|
Chest. 2006 Jun;129(6):1407-16 |
|
|
|
Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism
Ferretti G, Bria E, Giannarelli D, et al. |
|
Thromb Res. 2006 |
|
|